Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

Abstract

Objective. To investigate the functional ability i.e. the physical aspect of the health related quality of life and it's determining factors during therapy with etanercept in children with JIA.

Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis

“…Analyses of the improvement of functional ability due to treatment with etanercept in JIA patients including the newly approved categories of JIA have previously been published by Halbig and Horneff [8]. Data of 114 children with a complete data set and a continuous treatment for at least 24 months were used for this analysis.…”

“…Today, data on anti-TNF therapy in children with other than polyarticular courses are still limited [6][7][8][9][10][11][12]. Our study is able to provide both long-term safety and efficacy data for all JIA categories, taking advantage of the high numbers of patients and observation time in the BIKER registry.…”

New Treatment Strategies in the Treatment of Juvenile Idiopathic Arthritis

“…[36] Etanercept can induce disease remission and prevent both clinical and radiological disease progression with significant improvements in symptoms, function and quality of life. [37,38] In another small study, bone mineral status improved in patients who had responded to and continued etanercept treatment for more than one year. [39] Currently, little is known about when or how to stop etanercept in patients with JIA when a good clinical response is reached.…”

Tumor Necrosis Factor Inhibitors in the Management of Juvenile Idiopathic Arthritis

“…Over 1149 patient-years of exposure, 190 adverse events were reported. The rate of adverse events in the etanercept [39] Recent articles have focused on improvements in functional ability [57] and health-related quality-of-life outcomes [58] in children with JIA receiving etanercept. There is also a suggestion of amelioration in radiographic joint damage with etanercept in JIA.…”